HER2 Negative Breast Cancer Latest Advances

A prospective post-marketing observational study of abemaciclib in patients with HR+, HER2- breast cancer in China.

Journal: The oncologist

Published: October 01, 2025

Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report.

Journal: Journal of neuro-oncology

Published: July 31, 2025

Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2- breast cancer by PR positivity.

Journal: International journal of cancer

Published: July 05, 2025

Sequencing analysis reveals evidence of immune activation in advanced HER2 negative breast cancer responders treated with entinostat + nivolumab + ipilimumab.

Journal: Research square

Published: June 30, 2025

Correction to: Prognostic impact of ER‑staining patterns and heterogeneity of ER positive HER2 negative breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: June 09, 2025

Geographic variation in surgery rates among older patients with early (ER positive HER2 negative) breast cancer: Influence of cardiovascular disease and comorbidities: A national registry dataset analysis.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: May 29, 2025

Patient derived xenograft models of hormone receptor positive and HER2 negative breast cancer from Indian patients.

Journal: Scientific reports

Published: April 26, 2025

Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies.

Journal: Cancer treatment reviews

Published: April 24, 2025

Androgen Receptor Influenced Recurrence Score Correlation in Hormone Positive and HER2 Negative Breast Cancer Indian Patients: A Comparative Approach.

Journal: Genome integrity

Published: December 09, 2024

Prognostic impact of ER-staining patterns and heterogeneity of ER positive HER2 negative breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: December 06, 2024

A Review of Current Literature and Real-World Outcomes With Neoadjuvant Chemotherapy in Hormone Receptor Positive, HER2 Negative Breast Cancer.

Journal: Clinical breast cancer

Published: October 14, 2024

Predictive circulating biomarkers of the response to anti-PD-1 immunotherapy in advanced HER2 negative breast cancer.

Journal: Clinical and translational medicine

Published: September 27, 2024

HER2 Negative Breast Cancer Latest Advances

Find the Latest Research About HER2 Negative Breast Cancer

A prospective post-marketing observational study of abemaciclib in patients with HR+, HER2- breast cancer in China.

A prospective post-marketing observational study of abemaciclib in patients with HR+, HER2- breast cancer in China.

Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report.

Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report.

Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2- breast cancer by PR positivity.

Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2- breast cancer by PR positivity.

Sequencing analysis reveals evidence of immune activation in advanced HER2 negative breast cancer responders treated with entinostat + nivolumab + ipilimumab.

Sequencing analysis reveals evidence of immune activation in advanced HER2 negative breast cancer responders treated with entinostat + nivolumab + ipilimumab.

Correction to: Prognostic impact of ER‑staining patterns and heterogeneity of ER positive HER2 negative breast cancer.

Correction to: Prognostic impact of ER‑staining patterns and heterogeneity of ER positive HER2 negative breast cancer.

Geographic variation in surgery rates among older patients with early (ER positive HER2 negative) breast cancer: Influence of cardiovascular disease and comorbidities: A national registry dataset analysis.

Geographic variation in surgery rates among older patients with early (ER positive HER2 negative) breast cancer: Influence of cardiovascular disease and comorbidities: A national registry dataset analysis.

Patient derived xenograft models of hormone receptor positive and HER2 negative breast cancer from Indian patients.

Patient derived xenograft models of hormone receptor positive and HER2 negative breast cancer from Indian patients.

Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies.

Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies.

Androgen Receptor Influenced Recurrence Score Correlation in Hormone Positive and HER2 Negative Breast Cancer Indian Patients: A Comparative Approach.

Androgen Receptor Influenced Recurrence Score Correlation in Hormone Positive and HER2 Negative Breast Cancer Indian Patients: A Comparative Approach.

Prognostic impact of ER-staining patterns and heterogeneity of ER positive HER2 negative breast cancer.

Prognostic impact of ER-staining patterns and heterogeneity of ER positive HER2 negative breast cancer.

A Review of Current Literature and Real-World Outcomes With Neoadjuvant Chemotherapy in Hormone Receptor Positive, HER2 Negative Breast Cancer.

A Review of Current Literature and Real-World Outcomes With Neoadjuvant Chemotherapy in Hormone Receptor Positive, HER2 Negative Breast Cancer.

Predictive circulating biomarkers of the response to anti-PD-1 immunotherapy in advanced HER2 negative breast cancer.

Predictive circulating biomarkers of the response to anti-PD-1 immunotherapy in advanced HER2 negative breast cancer.